Greater Gift has announced a $50,000 scholarship to support a minority graduate student enrolled in Wake Forest University’s newly launched Master’s in Clinical Research Management Program. The scholarship is named in honor of Mary Hofmann Murphy, a Winston-Salem native and clinical research participant. The inaugural scholarship was awarded to Darius Ford of Raleigh, a student enrolled in the first cohort of students in the program.
Greater Gift is a non-profit, founded in 2010, with a mission to increase awareness of clinical research, especially among underrepresented communities. Greater Gift’s goal is to further the engagement of underrepresented groups in clinical research by investing in future leaders in the industry. Executive Director Lilly Skok Bunch stated, “We will only have real equity in clinical research participation when the research industry is reflective of our community. This scholarship is a step in that direction.”
The scholarship was named for Mary Hofmann Murphy, a participant in a cancer research trial conducted at Wake Forest Baptist Health with investigators from Wake Forest School of Medicine and Indiana University. “Mary Hofmann Murphy’s journey at Wake Forest Baptist Health is a story of commitment and a desire to help others, including those she may never know, who will benefit from her role in clinical research,” said Jennifer Byrne, Founder and Chair of the Board of Greater Gift. “Mary’s commitment to overcoming hardship and her wish to impact social justice in our world live in the spirit of this scholarship.”
The Master’s in Clinical Research Management program was created to increase the number of professionals entering into the clinical research industry.
For more information, click here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.